Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

29 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
No increased risk of glucose metabolism disorders in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from an observational, longitudinal study.
Beck-Peccoz P, Höybye C, Murray RD, Simsek S, Zabransky M, Zouater H, Stalla G. Beck-Peccoz P, et al. Among authors: zabransky m. BMC Endocr Disord. 2019 Dec 11;19(1):138. doi: 10.1186/s12902-019-0464-2. BMC Endocr Disord. 2019. PMID: 31829160 Free PMC article.
Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope®): data from the PATRO Adults study.
Beck-Peccoz P, Höybye C, Murray RD, Simsek S, Zabransky M, Zouater H, Stalla G. Beck-Peccoz P, et al. Among authors: zabransky m. Ther Adv Endocrinol Metab. 2020 Sep 10;11:2042018820943377. doi: 10.1177/2042018820943377. eCollection 2020. Ther Adv Endocrinol Metab. 2020. PMID: 32973992 Free PMC article.
PATRO children, a multi-center, non-interventional study of the safety and effectiveness of Omnitrope® (somatropin) treatment in children: update on the United States cohort.
Backeljauw P, Miller BS, Levy R, McCormick K, Zouater H, Zabransky M, Campbell K. Backeljauw P, et al. Among authors: zabransky m. J Pediatr Endocrinol Metab. 2021 Feb 26;34(4):431-440. doi: 10.1515/jpem-2020-0360. Print 2021 Apr 27. J Pediatr Endocrinol Metab. 2021. PMID: 33647196 Free article.
Safety and effectiveness of Omnitrope® (somatropin) in PATRO Children: a multi-center, post-marketing surveillance study comparison of US and international cohort data.
Backeljauw P, Kanumakala S, Loche S, Schwab KO, Miller BS, Levy R, McCormick K, Zouater H, Zabransky M, Campbell K. Backeljauw P, et al. Among authors: zabransky m. Eur J Pediatr. 2022 Jun;181(6):2367-2378. doi: 10.1007/s00431-022-04409-8. Epub 2022 Mar 11. Eur J Pediatr. 2022. PMID: 35275291 Free PMC article.
Design of, and first data from, PATRO Children, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope(®) in children requiring growth hormone treatment.
Pfäffle R, Schwab KO, Marginean O, Walczak M, Szalecki M, Schuck E, Zabransky M, Zucchini S. Pfäffle R, et al. Among authors: zabransky m. Ther Adv Endocrinol Metab. 2013 Feb;4(1):3-11. doi: 10.1177/2042018813479644. Ther Adv Endocrinol Metab. 2013. PMID: 23515245 Free PMC article.
29 results